Please login to the form below

Not currently logged in
Email:
Password:

Charity forms to tackle resistance to antibiotics

Antibiotic Research UK hopes to develop new drug in dive years
antibiotic research uk

A new UK organisation claims it is the world's first charity to tackle the growing public health threat of resistance to antibiotics.

York-based Antibiotic Research UK, or ANTRUK for short, was formed by members of the research network Antibiotic Discovery UK, including experts from 14 of the country's top universities and 14 biotech companies.

It aims to raise around £30m over the next five to seven years in order to bring at least one new antibiotic therapy to market.

New antibiotics are desperately needed as overuse of current treatments has led to growing resistance in infectious diseases.

However, despite this need, few drug development companies have committed to research new treatments, due primarily to the poor return on investment offered by the drugs.

The urgency has inspired national governments to implement measures to improve the research environment for companies, including new FDA incentives and a UK review to better understand how to support drug development.

ANTRUK is now the latest example of the growing realisation that tackling antimicrobial resistance has huge implications for global public health.

According to the charity, as antibiotics become ineffective many major surgeries will become impossible and new hips, knees, organ transplantation and many cancer treatments will become high risk.

The money raised will fund five scientific programmes identified by the charity's scientific and technical panel. The public will then decide which project to donate to.

According to ANTRUK, this method of funding “provides a direct link between public donors and the projects they are supporting”.

Prof Colin Garner, the chief executive of ANTRUK, added “The UK's charity sector has been extremely successful in raising funds for medical research and we hope to tap into this success; if we don't tackle the problem of antibiotic resistant bacteria now then the consequences will be far, far worse than the current Ebola outbreak.”

Article by
Thomas Meek

17th October 2014

From: Research, Marketing, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics